Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant for Sleep Quality in Rotating Shift Workers
NCT06496282Phase 3Recruiting
- Sponsor
- Phramongkutklao College of Medicine and Hospital
- Start
- Aug 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in shift work sleep disorder (SWSD) comparing Lemborexant 5 mg with Placebo (2 arms). Primary endpoints: Assessment effective of sleep quality at 6 weeks and Changing of Brian-derived neurotropic (BDNF) at 6 weeks. Started Aug 2024; status: recruiting.
02
Drugs
lemborexant
03
Conditions
shift work sleep disorder (SWSD)
Beyond the preview
Go deeper on NCT06496282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496282.